Atara Biotherapeutics (ATRA) Competitors $5.84 -0.14 (-2.34%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ATRA vs. ACTU, LYEL, GLSI, IKT, PRQR, FDMT, NMRA, LRMR, NGNE, and SCPHShould you be buying Atara Biotherapeutics stock or one of its competitors? The main competitors of Atara Biotherapeutics include Actuate Therapeutics (ACTU), Lyell Immunopharma (LYEL), Greenwich LifeSciences (GLSI), Inhibikase Therapeutics (IKT), ProQR Therapeutics (PRQR), 4D Molecular Therapeutics (FDMT), Neumora Therapeutics (NMRA), Larimar Therapeutics (LRMR), Neurogene (NGNE), and scPharmaceuticals (SCPH). These companies are all part of the "pharmaceutical products" industry. Atara Biotherapeutics vs. Actuate Therapeutics Lyell Immunopharma Greenwich LifeSciences Inhibikase Therapeutics ProQR Therapeutics 4D Molecular Therapeutics Neumora Therapeutics Larimar Therapeutics Neurogene scPharmaceuticals Atara Biotherapeutics (NASDAQ:ATRA) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, earnings, analyst recommendations and dividends. Does the media refer more to ATRA or ACTU? In the previous week, Actuate Therapeutics had 1 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 2 mentions for Actuate Therapeutics and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 1.89 beat Actuate Therapeutics' score of 0.94 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Atara Biotherapeutics Very Positive Actuate Therapeutics Positive Which has preferable earnings & valuation, ATRA or ACTU? Actuate Therapeutics has lower revenue, but higher earnings than Atara Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtara Biotherapeutics$128.94M0.27-$276.13M-$12.97-0.45Actuate TherapeuticsN/AN/A-$24.75MN/AN/A Do institutionals & insiders have more ownership in ATRA or ACTU? 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 3.7% of Atara Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts prefer ATRA or ACTU? Atara Biotherapeutics currently has a consensus price target of $17.75, suggesting a potential upside of 200.80%. Actuate Therapeutics has a consensus price target of $20.00, suggesting a potential upside of 146.61%. Given Atara Biotherapeutics' higher probable upside, equities analysts clearly believe Atara Biotherapeutics is more favorable than Actuate Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is ATRA or ACTU more profitable? Actuate Therapeutics has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -132.58%. Company Net Margins Return on Equity Return on Assets Atara Biotherapeutics-132.58% N/A -90.16% Actuate Therapeutics N/A N/A N/A Does the MarketBeat Community believe in ATRA or ACTU? Atara Biotherapeutics received 436 more outperform votes than Actuate Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Actuate Therapeutics an outperform vote while only 67.33% of users gave Atara Biotherapeutics an outperform vote. CompanyUnderperformOutperformAtara BiotherapeuticsOutperform Votes43767.33% Underperform Votes21232.67% Actuate TherapeuticsOutperform Votes1100.00% Underperform VotesNo Votes SummaryAtara Biotherapeutics beats Actuate Therapeutics on 8 of the 14 factors compared between the two stocks. Remove Ads Get Atara Biotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATRA vs. The Competition Export to ExcelMetricAtara BiotherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.57M$2.87B$5.32B$7.44BDividend YieldN/A1.91%5.11%4.32%P/E Ratio-0.2330.8121.7117.77Price / Sales0.27437.62371.6393.19Price / CashN/A168.6838.1534.64Price / Book-0.243.446.373.97Net Income-$276.13M-$72.06M$3.20B$247.34M7 Day Performance0.19%1.57%2.10%0.99%1 Month Performance-18.61%-18.23%-9.15%-6.65%1 Year Performance-65.37%-29.96%9.70%0.04% Atara Biotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATRAAtara Biotherapeutics4.3538 of 5 stars$5.84-2.3%$17.75+203.9%-64.8%$34.22M$128.94M-0.23330Positive NewsGap DownACTUActuate TherapeuticsN/A$6.82-1.0%$20.00+193.3%N/A$133.21MN/A0.0010Gap UpLYELLyell Immunopharma3.2279 of 5 stars$0.45-3.9%$1.00+123.9%-80.9%$131.85M$61,000.00-0.57270Analyst ForecastNews CoveragePositive NewsGap DownGLSIGreenwich LifeSciences1.9664 of 5 stars$9.59+8.6%$38.00+296.2%-37.2%$126.06MN/A-11.993Earnings ReportUpcoming EarningsNews CoverageGap DownHigh Trading VolumeIKTInhibikase Therapeutics1.4368 of 5 stars$1.68-8.7%$6.50+286.9%-13.4%$124.90M$260,000.00-0.636PRQRProQR Therapeutics2.1627 of 5 stars$1.17-0.8%$9.50+712.0%-41.8%$123.10M$18.91M-3.66180Short Interest ↓News CoverageFDMT4D Molecular Therapeutics2.5752 of 5 stars$2.65-4.3%$26.71+908.1%-88.2%$122.70M$37,000.00-0.93120Positive NewsNMRANeumora Therapeutics3.1659 of 5 stars$0.75+2.3%$9.29+1,132.8%-94.1%$122.00MN/A-0.40108LRMRLarimar Therapeutics3.5537 of 5 stars$1.87-4.6%$19.63+949.5%-74.2%$119.73MN/A-1.6330Positive NewsGap DownNGNENeurogene2.1149 of 5 stars$7.87-10.5%$53.00+573.4%-69.7%$117.50M$925,000.00-1.8490Analyst ForecastGap DownHigh Trading VolumeSCPHscPharmaceuticals3.753 of 5 stars$2.33+0.4%$14.00+500.9%-45.7%$117.16M$36.33M-1.2330Short Interest ↓Gap Down Remove Ads Related Companies and Tools Related Companies ACTU Alternatives LYEL Alternatives GLSI Alternatives IKT Alternatives PRQR Alternatives FDMT Alternatives NMRA Alternatives LRMR Alternatives NGNE Alternatives SCPH Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATRA) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredDOGE tax surpriseElon Musk's DOGE agents have some very strange plans for the IRS... Recently, it emerged that our tax auth...Altimetry | SponsoredIs it CRAZY to still want reliable profits, despite this market?Larry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredFirst look: The $3,500 iPhoneDid you hear that just before Trump's tariffs took effect, Apple sent five cargo planes packed with MacBooks a...Stansberry Research | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atara Biotherapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atara Biotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATRA Stock Free ATRA Stock Alerts